Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate

Sho Iwasaka, Yuji Shono, Kentaro Tokuda, Kosuke Nakashima, Yuzo Yamamoto, Jun Maki, Yoji Nagasaki, Nobuyuki Shimono, Tomohiko Akahoshi, Tomoaki Taguchi

Research output: Contribution to journalArticlepeer-review

Abstract

The number of people infected with severe acute respiratory syndrome coronavirus 2 is increasing globally, and some patients have a fatal clinical course. In light of this situation, the World Health Organization (WHO) declared coronavirus disease 2019 (COVID-19) a pandemic on March 11, 2020. While clinical studies and basic research on a treatment for COVID-19 are ongoing around the world, no treatment has yet been proven to be effective. Several clinical studies have demonstrated the efficacy of chloroquine phosphate and nafamostat mesylate with COVID-19. Here, we report the case of a Japanese patient with COVID-19 with severe respiratory failure who improved following the administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate. Hence, hydroxychloroquine with nafamostat mesylate might be a treatment option for severe COVID-19.

Original languageEnglish
Pages (from-to)1319-1323
Number of pages5
JournalJournal of Infection and Chemotherapy
Volume26
Issue number12
DOIs
Publication statusAccepted/In press - 2020

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate'. Together they form a unique fingerprint.

Cite this